STOCK TITAN

Bio-Rad Laboratories, Inc. Stock Price, News & Analysis

BIO.B NYSE

Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO.B), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.

Bio-Rad Laboratories, Inc. (BIO.B) delivers essential innovations across clinical diagnostics and life sciences, serving laboratories and researchers worldwide. This dedicated news hub provides investors and professionals with verified updates about the company's operational developments, financial milestones, and technological advancements.

Access real-time updates on earnings reports, regulatory filings, product launches, and strategic partnerships. Our curated feed covers both segments of Bio-Rad's business: clinical diagnostic solutions for laboratory testing and life science tools supporting biopharmaceutical development and food safety research.

Key focus areas include leadership in digital PCR technology, quality control systems for diagnostic labs, and updates regarding Bio-Rad's significant stake in Sartorius AG. Bookmark this page to monitor how the company maintains its market position across North America, Europe, and Asia-Pacific regions.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
buyback
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Bio-Rad Laboratories, Inc. (NYSE: BIO.B) will release its first-quarter 2023 financial results on May 4, 2023, after market close. A conference call is scheduled for 2 PM Pacific Time to discuss these results, with participation details available. Bio-Rad is recognized as a leader in life science research and clinical diagnostics, with a revenue of $2.8 billion in 2022. The company serves a wide range of customers including universities, hospitals, and biotech firms globally. For more information, the company’s Investor Relations section offers access to the webcast of the call. This will provide insights into the company’s performance and strategic direction as it progresses through the fiscal year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced its participation in a fireside chat at Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference. The event is scheduled for Thursday, March 2, 2023, at 11:45 AM Eastern Time (8:45 AM Pacific Time). A live webcast and replay will be available on the Investor Relations section of Bio-Rad's website. With over 70 years of expertise, Bio-Rad leads in life science research and clinical diagnostics, serving various sectors including healthcare and biotechnology. The company had approximately $2.8 billion in revenues in 2022, employing around 8,300 staff worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Bio-Rad Laboratories (BIO, BIOb) reported Q4 2022 net sales of $730.3 million, down 0.3% from Q4 2021, primarily due to a significant drop in COVID-related revenue. Life Science sales rose 10.1%, while Clinical Diagnostics declined 8.7%. Net income surged to $827.7 million, or $27.78 per share, from a net loss of $1.57 billion in Q4 2021, driven by fair market value changes in equity securities. For FY 2022, total sales decreased 4.1% to $2.8 billion, with a net loss of $3.63 billion. The company projects 6-7% non-GAAP currency-neutral revenue growth in 2023, citing a strong market recovery and operational improvements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Bio-Rad Laboratories (BIO.B)?

The current stock price of Bio-Rad Laboratories (BIO.B) is $257.75 as of July 11, 2025.

What is the market cap of Bio-Rad Laboratories (BIO.B)?

The market cap of Bio-Rad Laboratories (BIO.B) is approximately 6.8B.
Bio-Rad Laboratories, Inc.

NYSE:BIO.B

BIO.B Rankings

BIO.B Stock Data

6.81B
5.07M
Analytical Laboratory Instrument Manufacturing
Laboratory Analytical Instruments
Link
US
HERCULES